- Home
- PCRX vs OLPX Comparison
PCRX vs OLPX Comparison
Compare PCRX & OLPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PCRX
- OLPX
- Stock Information
- Founded
- PCRX 2006
- OLPX 2014
- Country
- PCRX United States
- OLPX United States
- Employees
- PCRX N/A
- OLPX N/A
- Industry
- PCRX Biotechnology: Pharmaceutical Preparations
- OLPX Package Goods/Cosmetics
- Sector
- PCRX Health Care
- OLPX Consumer Discretionary
- Exchange
- PCRX Nasdaq
- OLPX Nasdaq
- Market Cap
- PCRX 1.2B
- OLPX 1.0B
- IPO Year
- PCRX 2011
- OLPX 2021
- Fundamental
- Price
- PCRX $22.07
- OLPX $1.31
- Analyst Decision
- PCRX Buy
- OLPX Hold
- Analyst Count
- PCRX 8
- OLPX 4
- Target Price
- PCRX $28.38
- OLPX $1.88
- AVG Volume (30 Days)
- PCRX 590.9K
- OLPX 1.2M
- Earning Date
- PCRX 08-05-2025
- OLPX 08-07-2025
- Dividend Yield
- PCRX N/A
- OLPX N/A
- EPS Growth
- PCRX N/A
- OLPX N/A
- EPS
- PCRX N/A
- OLPX 0.02
- Revenue
- PCRX $702,772,000.00
- OLPX $420,742,000.00
- Revenue This Year
- PCRX $7.90
- OLPX $1.32
- Revenue Next Year
- PCRX $11.02
- OLPX $3.12
- P/E Ratio
- PCRX N/A
- OLPX $70.95
- Revenue Growth
- PCRX 3.08
- OLPX N/A
- 52 Week Low
- PCRX $11.16
- OLPX $1.01
- 52 Week High
- PCRX $27.64
- OLPX $2.77
- Technical
- Relative Strength Index (RSI)
- PCRX 44.39
- OLPX 40.81
- Support Level
- PCRX $20.85
- OLPX $1.32
- Resistance Level
- PCRX $22.32
- OLPX $1.71
- Average True Range (ATR)
- PCRX 0.84
- OLPX 0.10
- MACD
- PCRX 0.01
- OLPX -0.02
- Stochastic Oscillator
- PCRX 44.69
- OLPX 2.47
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
About OLPX Olaplex Holdings Inc.
Olaplex Holdings Inc is a science-enabled, technology-driven beauty company. It offers science-backed solutions that improve hair health. It identifies the majority of consumers' relevant haircare concerns in collaboration with the community of professional hairstylists and consumers and strives to address them through its proprietary technology and innovation capabilities. It offers products through an omnichannel platform that serves professional, specialty retail, and DTC channels. The company derives its revenue through the sale of its hair care products. The company generates the majority of revenue from Professional sales channels followed by Specialty Retail and then DTC. Geographically the company generates the majority of its revenue from the International market.